# A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants

> **NCT01177722** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 1375 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Whooping Cough
- Hepatitis B
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP-T Vaccine
- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP-T Vaccine
- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP-T Vaccine
- **BIOLOGICAL:** DTaP-Hep B-IPV vaccine

## Key facts

- **NCT ID:** NCT01177722
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-10
- **Final completion:** 2011-12
- **Target enrollment:** 1375 (ACTUAL)
- **Last updated:** 2014-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01177722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01177722, "A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01177722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*